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Many institutions are currently utilizing therapeutic hypother-
mia to target cardiac arrest as well as different types of brain in-
juries. Confounding issues including accidental hypothermia as
well as the need to carefully rewarm patients with some types of
physiological monitoring strategies are an area of active investiga-
tion and discussion. This particular session brought together ex-
perts in the field from cardiology, surgery, and trauma to discuss
current strategies for managing hypothermia and temperature
maintenance in various patients with different types of disorders.
Dr. Eric Zoog, medical director of the Emergency Department,
Mississippi Baptist Medical Center, provided an interesting sum-
mation of how he and his colleagues developed a successful hypo-
thermia program in a community hospital. Several important points
were made in terms of the processes, including convincing various
services to help with this important program. Dr. Robert Silbergleit,
Department of Emergency Medicine, University of Michigan Health
System, discussed his experience in various clinical trials, including
the use of hypothermia in cardiac arrest as well as patients undergoing
aneurysm surgery. His experience emphasized the importance of in-
troducing careful strategies to monitor brain function during cooling
and rewarming phases. Dr. Josh Levine, Department of Neurology,
University of Pennsylvania, discussed the use of hypothermia in
various brain injury conditions. Most importantly, he and his col-
leagues have been investigating the importance of developing surro-
gate biomarkers that could aid in the assessment of the status of the
brain. Most importantly, these biomarkers could be used to individ-
ualize treatments based on active processes. This session had a very
interesting question-and-answer exchange, again emphasizing the
interest in using therapeutic hypothermia and temperature manage-
ment strategies during various emergency situations.
Question: I think we want to do everything we can to mon-
itor the brain to see how it is doing. If we can develop ther-
apies that target individual subjects, that’s great. Do you
think we’ll be able to achieve that goal in the near future?
Most of the time, we are talking about trying to do clinical
studies that have a pretty rigid regimen predetermining what
we can do and what we cannot do. Then there is the expense of
using invasive or noninvasive techniques to monitor the
brain condition, or is this something that you see happening
globally in the near future?
Dr. Josh Levine: By nature, I am a realist, but here I’m opti-
mistic. I think that we have already seen this beginning to
occur in other fields of medicine. I’ll give you an example that
many of you in the room may be familiar with, which is goal-
directed therapy for sepsis. This was an emergency room–run
study showing that outcomes for sepsis could be improved by
following an algorithm. What I think was landmark about
that study was not that better outcomes were achieved, it was
the algorithm used. It incorporated things like central venous
oxygen saturation, which is much more relevant to physi-
ology than just keeping blood pressure above a certain arbi-
trary limit. They titrated the blood pressure and other
therapies, for example, blood transfusions, to achieve a certain
mixed venous oxygen saturation. So that is an example of
when a clinical trial was done with an algorithm. But the
algorithm was a step more sophisticated in my opinion than
the algorithms that we typically use, because they incorpo-
rated individualized physiology. I think that algorithms and
individualizing care are not mutually exclusive. They can be
done together. You just have to design the right algorithms.
To me, that was a landmark article for that reason and would
be the equivalent of titrating therapy for the brain using a
jugular venous oxygen saturation. We can do that. This
technology is cheap, it’s been around forever. It doesn’t re-
quire that much expertise to learn how to use it, so I am op-
timistic. I think a lot of the technology I showed is far-fetched
and will not make its way into the mainstream. But others
might, and I think that’s all we need. We need to be more
sophisticated about how we design our algorithms.
Dr. Robert Silbergleit: I think the big problem is figuring out
what to do with the information collected. What are the ef-
fective treatment algorithms used to respond to the moni-
toring? That’s the real challenge. That’s the threat to your
optimism. Early goal-directed therapy for sepsis followed a
dozen trials of late goal-directed therapy for sepsis that didn’t
work. Trials using pulmonary artery catheterization to guide
ICU therapy showed harm from the way the information was
used after 20 years of practice of pulmonary artery catheters.
Given the complexity of brain injury, and the potential insight
offered by a number of devices discussed, it makes sense to try
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to figure out how to make it all work. It makes perfect sense,
you’re right. I think the future is goal directed therapy. But in
terms of whether it is in our near future or not, I’m not so sure.
It’s a daunting challenge.
Dr. Josh Levine: I completely agree with everything you have
just said, and I think that in many ways in clinical medicine,
by necessity, we put the cart before the horse, and we study
things before we have a full understanding of the physiology.
I agree that this is a long-term goal. We need to understand
much better the physiology and which physiologic parame-
ters are really important, which ones aren’t. That is still
something that is debated. We need to understand the tech-
nology better, what are the risks, what are the benefits. A lot of
these algorithms employ bundles of therapy, and it is hard to
understand. If you include one thing in your bundle that is
harmful and the rest are beneficial, you might not see any
effect. It takes a long time to sort that out. I think that what I’m
advocating is that we start to think more this way, that just
broadly applying average values is not going to serve all of
our patients well. It looks nice for a clinical study, but it is not
necessarily the best way to treat patients. You’re right, I think
that there are centers like ours who are beginning to do this
but we’re studying it and trying to understand the physi-
ology. I’m optimistic that it will happen, but I also recognize
that it’s a long way off, and it’s exceptionally complex.
Dr. Robert Silbergleit: What about genotype?
Dr. Josh Levine: What about it? You mean incorporating
genetic data and individualizing care accordingly?
Dr. Robert Silbergleit: When individualizing care, it is not
just having these measurements, it is the fact that genotype
may have an effect.
Dr. Josh Levine: Absolutely, in brain injury that’s an area of
active research. This is a huge growth area in brain injury
research; we have very little concept of which alleles confer
benefit, which alleles confer harm. There is a little bit of data in
traumatic brain injury about ApoE, but it is very crude. You’re
right, that’s got to be incorporated someday into all of this. But
I think the physiology is the final key. No matter what your
genotype is, your physiology is what matters most in the ICU.
If you can at least measure the physiology, you can begin to
individualize therapy even without knowing the genotype.
But I do think genotype is important, as well.
Question: This is a great talk, and I agree with you. I think
that you need to individualize, but you do need some stan-
dardization. We can’t cool people all at different lengths of
time, at 12 hours, 24 hours, or at different temperatures—32,
33, 34C. So for a unit to be functional, you have to have some
kind of a base in which you have some standard practices.
Then when you round on individual patients, I think that you
have to be able to individualize. I think that what’s at risk
here, that the biggest unknown is the brain. I think we can
figure out the heart pretty quickly, if you go to the cath lab
and do all kinds of tests, have a pretty good feeling of what is
going on with the heart. But I’m always puzzled as what’s
going on with the brain. So we have patients at times with
hyperthermia becoming very profoundly bradycardic. We
wonder is it time to put a pacer in? Is it time to use dopamine?
Is it time to do something? A lot of times, we just back off. But
in backing off, are we doing harm to the brain? So do we need
some kind of way to monitor this? Not everybody has a
neuroICU-like approach. What would be your favorite way,
with people going away from a lot of Swans and hemody-
namic monitoring, is there a noninvasive way that is rela-
tively applicable and practical today for us to use with our
patients in our units?
Dr. Josh Levine: I think all of your points are excellent. I could
tell you what my favorite is, but I don’t have a lot of confidence
because I don’t think that these have been studied well enough
to actually make a recommendation. We use jugular bulb oxy-
metry, we use continuous EEG, we use all of the things I showed
you. But the easy ones, relatively easy, are jugular bulb oxy-
metry and EEG. I totally agree that you need standardization
for an ICU to run properly. But we have no problem titrating
pressors to achieve a certain goal. I would posit that perhaps in
the future, we’ll be titrating our hypothermia to achieve a cer-
tain goal, but it will be a meaningful physiologic goal. Why
should everybody be cooled for the same duration for the same
depth and then rewarmed at the same rate? They probably
shouldn’t. We just don’t know enough about how to do it, and I
think you can still standardize care by having algorithms that
incorporate a titration schedule—the way we do with pressors
or an insulin infusion or anything else that we titrate routinely
in the ICU without really even thinking about it.
Question: Is there any kind of relationship between the ele-
ments you can measure systemically—such as cardiac output
and cerebral blood flow? So for some patients, you can say, I
don’t need to worry about someone who has a great cardiac
output. Are there correlates from what we measure systemi-
cally; mixed venous O2’s that we can apply to the brain, as
well, so we don’t need to worry about this patient?
Dr. Josh Levine: Great question. That’s the key, and the an-
swer is no. There is such individual variability in the status of
what the blood vessels in the brain are doing from patient to
patient, even within the same patient, that you can’t just take
the systemic pressures that you are seeing and have any
confidence that you know what cerebral blood flow is. Even if
you know that cerebral blood flow is okay, are the cells able to
utilize the energy that is delivered? There are all sorts of dif-
ferent degrees of cellular energy failure, mitochondrial dys-
function, etc. So we just can’t do it, and that’s why I think we
need to evolve. If our goal is going to be to save brain tissue
and improve neurologic outcomes, we’ve got to, at some
point, evolve a way of treating patients that takes into account
the cerebral physiology. The only correlation I know is if your
blood pressure is zero, I can guarantee you the brain is not
doing well. Beyond that, it is very difficult to predict how the
brain is doing from systemic physiology.
Question: A question for Dr. Silbergleit. I was very interested
in your discussion of after-drop and the mechanism looking
at compartmentalization of heat in the body as you rewarm. I
wonder if you could help me understand something that
we’ve seen when we try to cool patients—that there are a fair
number of patients who will go to target very quickly. But
there are occasional patients that won’t or appear to go in a
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stepwise fashion. One of the theories is that if we administer
the cold saline first, before any anti-shivering measures are in
place—no skin warming, no Demerol—that there is a pe-
ripheral vasoconstriction that essentially isolates the pe-
riphery from the central. We are doing endovascular cooling.
Do you think there is anything to that? Or could there be
another explanation, or does what you taught us about after-
drop not even apply on the way down?
Dr. Robert Silbergleit: I think it probably does apply. There
was sort of this flurry of experimentation in the late 1980s
and ’90s in a number of physiology labs that didn’t really
seem to have a lot of clinical relevance except for our acci-
dental hypothermia patient population. I think that we start
to get a hint now that this work is probably relevant to the
therapeutic cooling that we’re doing commonly these days.
We need to look back and enhance those experiments. The
limited data that are available would suggest that the con-
vective mechanism isn’t a great explanation for why that is
happening. It is probably not safe to assume it, but I don’t
have a great explanation, for example, as to why it varies
from one patient to another patient. Clearly, the notion that
the human body is a big vat of water—that you can pour
some water in and it will equilibrate out and that will change
the temperature—was way wrong. How many compart-
ments communicate with each other is more complex and
probably discoverable.
Question: I have a question for Dr. Silbergleit, as well. With
profound hypothermia that is accidental, when you consider
that we are used to monitoring the hypothermia protocol for
cardiac arrest, what type of electrolyte monitoring or what
type of monitoring are you doing as you are trying to warm
these patients up basically as fast as you can? How fre-
quently are you checking your labs and things like that?
Dr. Robert Silbergleit: So again, this whole field has very
little data. The only real data that has been followed in these
avalanche victims is potassium, and that really just shows that
extremely high potassium levels are irreversible, and there is
good data that if you have a potassium level of 12, you cannot
be resuscitated.
Question:Do we have anything to say about if we want these
patients warmed quickly. How quick is too quick? Do we
look at these electrolyte shifts? Do we look at them hourly?
Do we look at them every two hours? What are our guidelines
for warming people quicker? Because I know from the cardiac
arrest experience, those that for some reason anecdotally are
warmed too quickly end up in cardiac arrest—a lot of them.
So I’m wondering, do we just ignore that and expect those
shifts? Or because they have been hypothermic for awhile, are
the shifts less extreme?
Dr. Robert Silbergleit: I’m not even entirely sure that the
anecdotal experience of not paying attention to electrolytes
during therapeutic hypothermia causes death. I think that that
needs to be investigated further. I think in the accidental hy-
pothermia population, it probably depends on patient factors
like duration of hypothermia and how long they were down
and what kind of preservation they had while they were hy-
pothermic. But as a general rule, there is nothing in the pub-
lished treatment algorithms that suggests that these patients
need to be followed closely or in any particular, certain dan-
gerous electrolyte shifts.
Question: Dr. Zoog, you mentioned that it took about a year
to establish hypothermia in your community hospital. I think
that is a pretty good success rate. Even at large university
hospitals, we talk about champions and someone with a vi-
sion, and you appear to be that person. Early on, who else
was supportive of what you were trying to achieve, and
again, how did that really happen in making a successful
program?
Dr. Eric Zoog:We were fortunate to have two intensivists that
were very interested. We have a situation in which there are
two intensivist groups that practice at the hospital, and one
group was very interested, the other not so much. You do run
into call issues for unreferred patients. The interested group
was interested enough to agree to take all the patients even if
the other group was on unreferred call. So that was an abso-
lute must, and then the nursing staff were critical as well. ICU
and ER nursing for us were the most affected, so our task force
included representatives from each of those areas.
Question: Where is the Level I trauma center located in
Mississippi?
Dr. Eric Zoog: In Jackson, about a half a mile from us. We
don’t have a whole lot of experience with hypothermia in the
trauma scenario for that reason.
Question: Do you have a good working relationship with
that hospital for transport and things like that?
Dr. Eric Zoog: The state trauma network has been around
now for 8 or 9 years. The nice thing about that is there are
prearranged agreements for transfer. You don’t have to go
through all the legalities to initiate a transfer of that sort. Our
trauma system director is very open to working with non-
trauma hospitals in providing care for trauma patients.
Question: The monitoring that we discussed, I really think
that is the future. The surrogate biomarker story is also going
to allow us to not only assess patients individually on how
well the brain is doing, but with the right biomarkers, we may
be able to assess the pathophysiology of what is going on in
the brain and how we can utilize novel therapies to target
those events in a time-dependent fashion. What do you think
about that, Dr. Bullock?
Comment: Yes, I absolutely agree that biomarkers are prob-
ably going to be the way of the future. However, the problem
is, some of the biomarkers, for example S100, we know are
contaminated by peripheral events. So long bone fractures
and soft tissue injuries can contaminate those reactions. I
think we are still searching for the best biomarker, but there
are some talks this afternoon that may address this. Then how
do you detect them in a kind of continuous ongoing way? One
comment that I was going to make is that the medical device
community has done us a big disservice over the years. When
you think of what a pilot does when he is flying an F15, you
get a million sensors bringing information in; the information
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gets processed down so that it is understandable by one
person second to second. Whereas, with us in the medical
device area, we have a million different languages that the
different computers speak. GE machines don’t talk to space
lab machines and so trying to integrate all these different
forms of sensors that Dr. Levine showed very elegantly is
difficult. We have to figure out a better way to follow the
streams of data—maybe these dashboards that you see, where
five different parameters are going red at one time, which
means you have to do something. Perhaps systems science
has progressed so much that it can be brought to bear in our
fields better. I wonder whether the critical care medicine so-
ciety and other professional groups have to be the leaders.
Comment: That is a good point. I just wanted to say that now
we have special units that are monitoring ICUs because the
data is so complex. St. Lukes in Milwaukee and several other
hospitals have central ICU monitoring stations where doctors
and nurses are basically monitoring the data to look for errors
of omission by someone not aware that certain data changes
are very important. So it is getting very complex. We do need
that cockpit.
Question: I was also interested—in terms of our previous
discussion—in how long we are cooling in cardiac arrest
patients. Am I correct in saying that most people are cooling
for about 24 hours? Yesterday we saw some interesting bio-
marker data showing that elevated levels would go on for 72
plus hours. I think that’s an area that we really should be
thinking about. Maybe some cardiac arrest patients are going
to do well with a 24-hour cooling period, but others are going
to have to go longer, so we need to consider durations. I guess
my question to the panel is, when we talk about duration in
terms of cardiac arrest, do we need to prolong the hypother-
mia to protect the heart, or are we prolonging the hypother-
mia to protect the brain, or both?
Dr. Josh Levine: I think, simplistically, both. Because of the
bent in our ICU, which is a neurologic bent, we’ll often extend
the duration of hypothermia based on what we are seeing
physiologically in the brain. So, for example, if we have a
continuous EEG, which we do on all these patients, and they
start to have seizures during rewarming, we’ll recool them.
We’ll keep trying until the seizures go away. If we see that the
intracranial pressure rises dramatically during rewarming,
we’ll either slow it down, or we’ll back off and recool them. So
I think there’s really no way at this point to monitor how it is
going to impact survival. We are beginning to have ways to
monitor how it is impacting brain physiology, but we are far
from knowing what the right thing to do is. The job of a
physician is to use the best available evidence and, where
there is no evidence, to use clinical judgment based on un-
derstanding of physiology. And so that’s all we can do at this
point. In our ICU, we often modify the hypothermia protocol
for brain physiology reasons. I’m not aware of how we would
modify it for survival reasons at this point.
Dr. Robert Silbergleit: So there is a difference between saying
that titrating therapy is the wave of the future and saying that
that is what we need to do now for every therapy. There are a
couple of reasons why you might want to titrate duration
rather than just study the effects of different durations for
everybody. Certainly, there is a danger to every additional
day that you are in the ICU, right? I mean, being in the ICU is a
hazardous thing to be. So there are good reasons to limit one’s
ICU exposure. But whether that is enough to necessarily re-
quire that duration be titrated, does that create a narrow
therapeutic index? Or is the therapeutic index still large? If the
therapeutic index is large, there is less of a need for titration. I
suspect that a few extra days of therapeutic hypothermia is
not so hazardous and may be beneficial. I’m not sure that this
is the first place that we have to look toward goal-directed
therapy, but we do need a trial to compare durations of
cooling in less severe and more severe injuries.
Question: People already use radioisotope-labeled pharma-
ceuticals for cardiac mass perfusion imaging and brain per-
fusion imaging. So I don’t know whether there is application
of nuclear medicine like single-photon emission computed
tomography (SPECT), computerized axial tomography (CAT)
scans in ICU patients, to monitor their cardiac function and
brain function simultaneously.
Dr. Eric Zoog: I think the difficult part is actually getting those
studies done. We have a huge resistance to actually moving
these patients. I don’t know if those studies are portable en-
ough. I would have to convince our facility that it is a good
idea. The intravascular management system that we use does
not have a battery on it. So I have to disconnect the patient
from it to get the testing done if it’s not able to be done in the
unit. Just a potential confounding factor we would have to
figure a way around.
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